Literature DB >> 27804122

Calcineurin Inhibitors: Pharmacologic Mechanisms Impacting Both Insulin Resistance and Insulin Secretion Leading to Glucose Dysregulation and Diabetes Mellitus.

H A Chakkera1, Y Kudva2, B Kaplan1.   

Abstract

Calcineurin inhibitors (CNIs), including tacrolimus and cyclosporine, are immune-modulating agents used in autoimmune disorders, glomerulonephritides, and after transplantation. CNIs are implicated as diabetogenic drugs but the mechanism is not clearly elucidated. Calcineurin is a cytosolic-phosphatase critical for T-lymphocyte activation. Calcineurin is widely distributed in different tissues responsible for glucose-regulation including pancreas, liver, skeletal muscle, adipocytes, brain, and gut. We describe the pharmacologic effects of CNIs in different tissues and impact on glucose regulation.
© 2016 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27804122     DOI: 10.1002/cpt.546

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  24 in total

1.  Calcineurin inhibitor-associated new-onset diabetes mellitus in chronic kidney disease treatment: a 4-year single-center cross-sectional study in China.

Authors:  Pan Kun-Ming; Chen Can; Xu Qing; Wu Wei; Lv Qian-Zhou; Li Xiao-Yu
Journal:  Eur J Clin Pharmacol       Date:  2021-01-23       Impact factor: 2.953

2.  [Correlation of blood concentration of tacrolimus with serum cystatin C in renal transplant recipients and effect of tacrolimus on glucose and lipid metabolism].

Authors:  Zhen-Bang Zhong; Li-Qian Mo; Yan Chen; Ping Zheng; Xi-Xiao Yang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-06-20

3.  The circFASN/miR-33a pathway participates in tacrolimus-induced dysregulation of hepatic triglyceride homeostasis.

Authors:  Chenzhi Zhang; Kangchen Chen; Rongli Wei; Guanghan Fan; Xuechun Cai; Li Xu; Beini Cen; Jianguo Wang; Haiyang Xie; Shusen Zheng; Xiao Xu
Journal:  Signal Transduct Target Ther       Date:  2020-03-27

4.  Adverse Events under Tacrolimus and Cyclosporine in the First 3 Years Post-Renal Transplantation in Children.

Authors:  Pauline Lancia; Beate Aurich; Phuong Ha; Anne Maisin; Véronique Baudouin; Evelyne Jacqz-Aigrain
Journal:  Clin Drug Investig       Date:  2018-02       Impact factor: 2.859

5.  Effects of Immunosuppressive Medications on Mitochondrial Function.

Authors:  Amanda Nash; Mariya Samoylova; Tess Leuthner; Minghua Zhu; Liwen Lin; Joel N Meyer; Todd V Brennan
Journal:  J Surg Res       Date:  2020-01-06       Impact factor: 2.192

Review 6.  Extrahepatic organs in the development of non-alcoholic fatty liver disease in liver transplant patients.

Authors:  Renyi Su; Xuyong Wei; Qiang Wei; Di Lu; Zuyuan Lin; Shuo Wang; Chuxiao Shao; Xiao Xu
Journal:  Hepatobiliary Surg Nutr       Date:  2022-06       Impact factor: 8.265

7.  Glucose metabolism disorders in children with refractory nephrotic syndrome.

Authors:  Toshiyuki Takahashi; Takayuki Okamoto; Yasuyuki Sato; Asako Hayashi; Yasuhiro Ueda; Tadashi Ariga
Journal:  Pediatr Nephrol       Date:  2020-01-16       Impact factor: 3.714

8.  Clinical practice guideline on pregnancy and renal disease.

Authors:  Kate Wiles; Lucy Chappell; Katherine Clark; Louise Elman; Matt Hall; Liz Lightstone; Germin Mohamed; Durba Mukherjee; Catherine Nelson-Piercy; Philip Webster; Rebecca Whybrow; Kate Bramham
Journal:  BMC Nephrol       Date:  2019-10-31       Impact factor: 2.388

Review 9.  Reproductive health and pregnancy in women with chronic kidney disease.

Authors:  Kate S Wiles; Catherine Nelson-Piercy; Kate Bramham
Journal:  Nat Rev Nephrol       Date:  2018-01-22       Impact factor: 28.314

Review 10.  Prevention of complications from use of conventional immunosuppressants: a critical review.

Authors:  Claudio Ponticelli; Richard J Glassock
Journal:  J Nephrol       Date:  2019-03-29       Impact factor: 4.393

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.